DeepMed Research

Lurasidone

Generic Name: Lurasidone

Brand Names: Latuda

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₆N_₄O_₂S

CAS Number: 367514-87-2

Unique Ingredient Identifier: 22IC88528T

Background: Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.

Indication: Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.

Associated Conditions: Depression, Bipolar, Schizophrenia

Clinical Trials

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Other: Placebo
Drug: lurasidone

First Posted Date: 2016-04-07

Last Posted Date: 2025-02-14

Lead Sponsor: Lakshmi N Yatham

Target Recruit Count: 100

Registration Number: NCT02731612

Locations: 🇺🇸
The Brigham and Women's Hospital, Department of Psychiatry, Boston, Massachusetts, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇨🇦
UBC Mood Disorders Center, Vancouver, British Columbia, Canada

and more 6 locations

Biosignatures of Latuda for Bipolar Depression

Not Applicable

Completed

Conditions: Bipolar Depression

Interventions: Drug: Lurasidone (Latuda)

First Posted Date: 2014-09-12

Last Posted Date: 2017-12-12

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 20

Registration Number: NCT02239094

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Lurasidone
Drug: Haloperidol
Drug: Perphenazine

First Posted Date: 2014-07-24

Last Posted Date: 2021-03-01

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 35

Registration Number: NCT02199743

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: 20mg lurasidone
Drug: 40mg lurasidone
Drug: 80mg lurasidone
Drug: placebo

First Posted Date: 2014-06-25

Last Posted Date: 2019-01-11

Lead Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT02174510

Locations: 🇨🇳
Xuhui Center Hospital, Shanghai, Shanghai, China

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: 40mg lurasidone
Drug: placebo

First Posted Date: 2014-06-25

Last Posted Date: 2019-04-08

Lead Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT02174523

Locations: 🇨🇳
Xuhui Center Hospital, Shanghai, Shanghai, China

Lurasidone and Cognition in Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Lurasidone

First Posted Date: 2014-05-26

Last Posted Date: 2017-02-02

Lead Sponsor: University of British Columbia

Target Recruit Count: 53

Registration Number: NCT02147379

Locations: 🇨🇦
University of British Columbia, Department of Psychiatry, Vancouver, British Columbia, Canada

Lurasidone Pediatric Bipolar Study

Phase 3

Completed

Conditions: Bipolar I Depression

Interventions: Drug: Placebo
Drug: Lurasidone

First Posted Date: 2014-01-27

Last Posted Date: 2017-12-20

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 350

Registration Number: NCT02046369

Locations: 🇺🇸
Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States

and more 63 locations

A Clinical Trial of Lurasidone in Treatment of Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Lurasidone tablets
Drug: Risperidone tablets

First Posted Date: 2013-12-06

Last Posted Date: 2019-11-15

Lead Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.

Target Recruit Count: 388

Registration Number: NCT02002832

Locations: 🇨🇳
Guangzhou Brain Hospital, Guangzhou, Guangdong, China
🇨🇳
HeBei Mental Health Center, Baoding, Hebei, China
🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China

and more 12 locations

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Phase 3

Completed

Conditions: Bipolar Depression

Interventions: Drug: Placebo
Drug: SM-13496

First Posted Date: 2013-11-18

Last Posted Date: 2022-04-12

Lead Sponsor: Sumitomo Pharma Co., Ltd.

Target Recruit Count: 525

Registration Number: NCT01986101

Locations: 🇯🇵
Japan 76 sites, Tokyo, Japan
🇱🇹
Lithuania 3 sites, Kaunas, Lithuania
🇲🇾
Malaysia 5 sites, Kuala Lumpur, Malaysia

and more 5 locations

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: SM-13496

First Posted Date: 2013-11-18

Last Posted Date: 2022-04-12

Lead Sponsor: Sumitomo Pharma Co., Ltd.

Target Recruit Count: 495

Registration Number: NCT01986114

Locations: 🇺🇦
Ukraine 9 sites, Kiev, Ukraine
🇸🇰
Slovakia 5 sites, Zilina, Slovakia
🇲🇾
Malaysia 5 sites, Kuala Lumpur, Malaysia

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy